scholarly journals Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis

2017 ◽  
Vol 15 (9) ◽  
pp. 1359-1372.e6 ◽  
Author(s):  
Yun Qiu ◽  
Ren Mao ◽  
Bai-li Chen ◽  
Sheng-hong Zhang ◽  
Jing Guo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Combination Therapy ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Meta Analysis ◽  
Tumor Necrosis Factor Antagonists ◽  
Inflammatory Bowel ◽  
Trough Levels ◽  
Necrosis Factor

scholarly journals Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

JAMA ◽  
2017 ◽  
Vol 318 (17) ◽  
pp. 1679 ◽  
Author(s):  
Magali Lemaitre ◽  
Julien Kirchgesner ◽  
Annie Rudnichi ◽  
Fabrice Carrat ◽  
Mahmoud Zureik ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Antagonists ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease

2017 ◽  
Vol 15 (1) ◽  
pp. 25-36.e27 ◽  
Author(s):  
Laurent Peyrin-Biroulet ◽  
Gert Van Assche ◽  
David Gómez-Ulloa ◽  
Laura García-Álvarez ◽  
Núria Lara ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Extraintestinal Manifestations ◽  
Tumor Necrosis Factor Antagonists ◽  
Inflammatory Bowel ◽  
Necrosis Factor

scholarly journals Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease

2021 ◽  
Vol 8 ◽  
Author(s):  
Israa Abdullah ◽  
Ghadeer Alhendi ◽  
Anwar Alhadab ◽  
Hajer Alasfour ◽  
Mohammad Shehab
Keyword(s):  
Inflammatory Bowel Disease ◽  
Tumor Necrosis Factor ◽  
Combination Therapy ◽  
Interest Group ◽  
Antibody Level ◽  
Bowel Disease ◽  
Tumor Necrosis ◽  
Antidrug Antibody ◽  
Inflammatory Bowel ◽  
Necrosis Factor

Introduction: Tumor necrosis factor antagonists (anti-TNF) therapies are used for the management of moderate to severe inflammatory bowel disease (IBD). Anti-TNF combination therapy, with immunomodulators, has been shown to reduce immunogenicity, especially for infliximab, improve treatment success rate and patient outcomes. We evaluated factors associated with gastroenterologists adherence to anti-TNF combination therapy.Methods: A retrospective cohort study was performed to evaluate the adherence of gastroenterologists (n = 14), at an inflammatory bowel disease center, to anti-TNF combination therapy. Records of patients who received Infliximab (n = 137) or adalimumab (n = 152) were obtained and their ordering physicians' data was analyzed. Gastroenterologists were divided into six groups according to their age and interest in IBD. The baseline characteristics of their patients were also obtained.Results: The proportion of patients on combination therapy in the young gastroenterologists group was higher than those in the senior gastroenterologists group for both infliximab (83.2 vs. 55.6%, respectively, P < 0.001) and adalimumab (59 vs. 30.8%, respectively, P < 0.001). Gastroenterologists with interest in inflammatory bowel disease (IBD interest group) had also more proportion of patients on adalimumab combination therapy compared to gastroenterologists with no interest in IBD (non-IBD interest group) (61.7 vs. 35.2%, respectively, P < 0.001). Gastroenterologists who were both young and have interest in IBD had more proportion of patients on combination therapy than those who were senior or had no interest in IBD for both infliximab (89.4 vs. 63.4%, respectively, P < 0.001) and adalimumab (75.9 vs. 33%, P < 0.001). The IBD interest group was also requesting more antidrug antibody level tests than those in the non-IBD interest group (41.4 vs. 12.3 tests, respectively, P < 0.001).Conclusion: Young gastroenterologists are more likely to prescribe anti-TNF infliximab and adalimumab combination therapy than senior gastroenterologists. In addition, gastroenterologists with IBD interest are more likely to prescribe adalimumab combination therapy than gastroenterologists with no IBD interest. Moreover, young gastroenterologists who have interest in IBD are more likely to prescribe both infliximab and adalimumab combination therapy than senior gastroenterologists or those with no IBD interest. In addition, gastroenterologists with IBD interest requested more anti-TNF serum drug concentrations and antidrug antibody level tests than those with no IBD interest.

Sign in / Sign up

Export Citation Format

Share Document